The propose epidemiologic family study will systematically examine the vulnerability to nicotine dependence due to the combined transmission of genes and family/cultural environmental factors (e.g., familial liability). Four areas are addressed in the proposed study: 1) the familial liability for nicotine dependence associated with different phenotypes or characteristics of nicotine dependence (e.g. also meeting DSM-IV criteria); 2) the degree of shared familial liability dependence and non- familial environmental factors in the etiology of nicotine dependence; 4) familial liability, non-familial factors, and individual factors that may be partially under genetic control (such as nicotine metabolism) that contribute to estimated differences in nicotine dependence between African Americans and Caucasians, both to spotlight factors that contribute to nicotine dependence in a group at high risk of cancer mortality (African Americans) and to identify protective factors by comparing racial groups with substantially different cigarette smoking profiles. This epidemiologic case-control family study is designed to examine the familial transmission of nicotine dependence among adults 25 to 44 years of age and their families. This range will be used because the period of risk for daily smoking is largely concluded by age 25 and adults between these ages are still likely to have living parents. Cases will be nicotine dependent by a threshold score of 4 or more on the Fagerstrom Test of Nicotine Dependence (FTND). Controls will be smoking exposed (having smoked at least 100 cigarettes) but never nicotine dependent (FTND=0). For cases on sibling and both parents will be sought. For controls one sibling will be sought. Direct interviews will be conducted with the case and control family members. The information gathered will include their cigarette smoking, psychiatric disorders, and other substance use, as well as demographic and medical history information. All of the interviewed family members will provide family history of cigarette smoking, substance use and psychiatric disorders. Additionally, cases and controls will be asked about the cigarette smoking, alcohol use and behavior problems of their offspring. This study provides a population-based context for genetic and metabolism studies in the Collaborative Study on the Genetics of Nicotine Dependence. Ascertainment, interviewing, and data management will be integrated across studies. Additionally, as part of the unique opportunity presented by the scientific integration of Projects 1, 2, and 3 we will incorporate genetic, metabolic and epidemiologic measures of a broad array for factors in the development of risk factor models for nicotine dependence.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HD031313-09
Application #
6343165
Study Section
Special Emphasis Panel (ZHD1-DRG-H (02))
Program Officer
Grave, Gilman D
Project Start
1994-01-01
Project End
2003-12-31
Budget Start
2001-01-01
Budget End
2001-12-31
Support Year
9
Fiscal Year
2001
Total Cost
$470,862
Indirect Cost
Name
Children's Mercy Hosp (Kansas City, MO)
Department
Type
DUNS #
City
Kansas City
State
MO
Country
United States
Zip Code
64108
Jones, Bridgette L; Kearns, Gregory; Neville, Kathleen A et al. (2013) Variability of histamine pharmacodynamic response in children with allergic rhinitis. J Clin Pharmacol 53:731-7
Kearns, Gregory L; Leeder, J Steven; Gaedigk, Andrea (2010) Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 38:894-7
Leeder, J Steven; Kearns, Gregory L; Spielberg, Stephen P et al. (2010) Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 50:1377-87
Blake, Michael J; Abdel-Rahman, Susan M; Pearce, Robin E et al. (2006) Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 60:717-23
Pearce, Robin E; Leeder, J Steven; Kearns, Gregory L (2006) Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos 34:1035-40
Capparelli, Edmund V; Reed, Michael D; Bradley, John S et al. (2005) Pharmacokinetics of gatifloxacin in infants and children. Antimicrob Agents Chemother 49:1106-12
Blake, Michael J; Castro, Lisa; Leeder, J Steven et al. (2005) Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 10:123-38
James, Laura P; Simpson, Pippa M; Farrar, Henry C et al. (2005) Cytokines and toxicity in acetaminophen overdose. J Clin Pharmacol 45:1165-71
Kennedy, Mary Jayne; Jackson, Mary Anne; Kearns, Gregory L (2004) Delayed diagnosis of penicillin-resistant Streptococcus mitis endocarditis following single-dose amoxicillin prophylaxis in a child. Clin Pediatr (Phila) 43:773-6
Kennedy, Mary Jayne; Abdel-Rahman, Susan M; Kashuba, Angela D M et al. (2004) Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol 44:708-14

Showing the most recent 10 out of 41 publications